A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab

被引：17
作者：
Sugiura, Fumiaki [1 ]
Kojima, Toshihisa
Oguchi, Takeshi [1 ]
Urata, Shirou [1 ]
Yuzawa, Yukio [2 ]
Sakakibara, Akihiro [3 ]
Hayashi, Hiroki [2 ]
Nishimoto, Norihiro [4 ]
Ishiguro, Naoki
机构：
[1] Anjo Kosei Hosp, Dept Orthoped Surg, Aichi 4668602, Japan
[2] Nagoya Univ, Sch Med, Dept Clin Immunol, Nagoya, Aichi 466, Japan
[3] Nagoya Univ, Sch Med, Dept Dermatol, Nagoya, Aichi 466, Japan
[4] Osaka Univ, Lab Immune Regulat, Grad Sch Frontier Biosci, Osaka, Japan
来源：
MODERN RHEUMATOLOGY | 2009年 / 19卷 / 02期
基金：
巴西圣保罗研究基金会; 英国医学研究理事会; 新加坡国家研究基金会; 英国惠康基金; 芬兰科学院;
关键词：
Tocilizumab; Rheumatoid arthritis; Skin ulcer; Peripheral neuropathy; LEUKOCYTOCLASTIC VASCULITIS; CONTROLLED-TRIAL; GROWTH-FACTOR; DOUBLE-BLIND; INTERLEUKIN-6; ANTIBODY; THERAPY;
D O I：
10.1007/s10165-008-0132-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We report a case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis (RA) who received tocilizumab. A 65-year-old woman with a 20-year history of RA participated in a tocilizumab clinical trial. She received a single dose of 8 mg/kg tocilizumab intravenously. The following day the patient started to experience numbness and purpura in all four extremities. The purpura of her left lower limb became necrotic, and a skin ulcer appeared 3 weeks later. Steroid-pulse treatment was initiated 12 weeks after tocilizumab administration, with the result that the numbness improved, and the skin ulcers showed complete epithelialization.
引用
收藏
页码：199 / 203
页数：5
相关论文
共 11 条
[1]  
Jarrett SJ, 2003, J RHEUMATOL, V30, P2287
[2]   Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate [J].
Maini, R. N. ;
Taylor, P. C. ;
Szechinski, J. ;
Pavelka, K. ;
Broell, J. ;
Balint, G. ;
Emery, P. ;
Raemen, F. ;
Petersen, J. ;
Smolen, J. ;
Thomson, D. ;
Kishimoto, T. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2817-2829
[3]  
Mohan N, 2004, J RHEUMATOL, V31, P1955
[4]   Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial [J].
Nishimoto, N ;
Yoshizaki, K ;
Miyasaka, N ;
Yamamoto, K ;
Kawai, S ;
Takeuchi, T ;
Hashimoto, J ;
Azuma, J ;
Kishimoto, T .
ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1761-1769
[5]   Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab [J].
Nishimoto, Norihiro ;
Hashimoto, Jun ;
Miyasaka, Nobuyuki ;
Yamamoto, Kazuhiko ;
Kawai, Shinichi ;
Takeuchi, Tsutomu ;
Murata, Norikazu ;
van der Heijde, Desiree ;
Kishimoto, Tadamitsu .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1162-1167
[6]   Interieukin-6 in rheumatoid arthritis [J].
Nishimoto, Norihiro .
CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (03) :277-281
[7]   Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody [J].
Ogawa, J. ;
Harigai, M. ;
Akashi, T. ;
Nagasaka, K. ;
Suzuki, F. ;
Tominaga, S. ;
Miyasaka, N. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1667-1669
[8]  
Richette P, 2004, J RHEUMATOL, V31, P2079
[9]   Vasculitides induced by TNFα antagonists:: a study in 39 patients in France [J].
Saint Marcoux, Bernadette ;
De Bandt, Michel .
JOINT BONE SPINE, 2006, 73 (06) :710-713
[10]   Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells [J].
Tamm, M ;
Bihl, M ;
Eickelberg, O ;
Stulz, P ;
Perruchoud, AP ;
Roth, M .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 19 (04) :653-661
12